select trial semaglutide cardiovascular outcomes non-diabetic 2023 and in patients with obesity and prevalent heart failure: a prespecified analysis of the A trial emulation in Nature

SKU: 91055492753

Pay in 4 interest-free payments of $6.04 Learn more

Live Spec

A trial emulation in Nature Medicine shows that treatment with semaglutide and tirzepatide showed similar levels of benefit on cardiovascular outcomes in people at elevated cardiovascular risk with obesity and diabetes. Link Frontiers Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial The Lancet Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week JACC A new analysis of the SELECT trial confirms that semaglutide lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they Semaglutide and the Heart: clinical insights from the SELECT Trial

Store: skntheory.com · Domain: skntheory.com